Effects of empagliflozin on lipoprotein subfractions in patients with type 2 diabetes: data from a randomized, placebo-controlled study-Reference-Cited by-同舟云学术

Effects of empagliflozin on lipoprotein subfractions in patients with type 2 diabetes: data from a randomized, placebo-controlled study

Published:2021-08 Issue: Volume:330 Page:8-13
ISSN:0021-9150
Container-title:Atherosclerosis
language:en
Short-container-title:Atherosclerosis

Author:

Rau Matthias^ORCID,Thiele Kirsten,Korbinian Hartmann Niels-Ulrik,Möllmann Julia,Wied Stephanie^ORCID,Böhm Michael,Scharnagl Hubert,März Winfried,Marx Nikolaus,Lehrke Michael

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine

Reference34 articles.

1. Probing SGLT2 as a therapeutic target for diabetes: basic physiology and consequences;Gallo;Diabetes Vasc. Dis. Res.,2015

2. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes;Zinman;N. Engl. J. Med.,2015

3. Canagliflozin and cardiovascular and renal events in type 2 diabetes;Neal;N. Engl. J. Med.,2017

4. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy;Perkovic;N. Engl. J. Med.,2019

5. Dapagliflozin and cardiovascular outcomes in type 2 diabetes;Wiviott;N. Engl. J. Med.,2019

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Update on the clinical applications of SGLTis: Insight to benefits beyond hypoglycemic and cardiorenal protection;Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy;2024-07-08

2. Effect of sodium–glucose cotransporter 2 inhibitors on serum low‐density lipoprotein cholesterol in Japanese patients with type 2 diabetes mellitus;Journal of Diabetes Investigation;2024-03-08

3. Empagliflozin improves aortic injury in obese mice by regulating fatty acid metabolism;Open Medicine;2024-01-01

4. SGLT2 inhibition, circulating metabolites, and atrial fibrillation: a Mendelian randomization study;Cardiovascular Diabetology;2023-10-17

5. Empagliflozin improves high-sensitive cardiac troponin-I and high-density lipoprotein cholesterol in patients with type 2 diabetes mellitus and coronary artery disease: a post-hoc analysis of EMPA-CARD Trial;Journal of Diabetes & Metabolic Disorders;2023-09-22